OXFORD, UK. December 23rd, 2024 - A pioneering team of Oxford researchers from Oxperial BioHealth has unveiled Green Products Photodynamic Therapy (GPDT), a revolutionary photodynamic composition that has captured global attention at the 2024 Pharmaceutical Science Conference in Barcelona and the 20th Guangzhou International Symposium on Molecular Medicine. Branded as “Sunshine Against Cancer,” this innovation marks a significant advancement in cancer research.
Led by Dr. Daniel T. H. Chen, Dr. Ta-Chun Liu, Pharmacist Shin-Yi Huang, and Dr. Yao-Kuan Chen, the team demonstrated that GPDT—a pure, plant-based composition—induces apoptosis (programmed cell death) in human cancer cells, a process significantly enhanced by sunlight exposure. The therapy harnesses the therapeutic properties of plant chlorophyll and other natural compounds, presenting a potential sustainable and non-invasive alternative to conventional treatments.
The team’s work has already secured patents in the UK and Taiwan, with multinational patent protections currently underway. GPDT’s ability to inhibit tumour cell growth and differentiation positions it as a groundbreaking development in oncology. This eco-friendly and innovative approach integrates photodynamic activation with natural ingredients, positioning it as a novel tool in global cancer research and care.
The international medical and pharmaceutical communities have shown great interest in this breakthrough, positioning GPDT as a potential game-changer in the fight against one of humanity’s most challenging diseases. Could sunlight hold the key to a brighter, healthier future with new possibilities for cancer treatment? The answer may be closer than ever.
Cancer continues to be the leading cause of death globally, but a groundbreaking innovation could change the game. At the 2024 Barcelona Global Pharmacology Symposium, Dr. Daniel T. H. Chen from Oxford University presented cutting-edge findings on GPDT (Green Products Photodynamic Therapy), a revolutionary photodynamic preparation that leverages sunlight and natural plant compounds to target cancer cells at the cellular level.
GPDT utilises the 400nm-700nm wavelength range of sunlight to activate natural plant components, generating reactive oxygen species, including single-state oxygen molecules, which have demonstrated cancer cell inhibitory effects in laboratory studies. This approach is positioned as a non-invasive and complementary wellness option for those seeking alternatives to traditional methods often associated with significant side effects.
“GPDT is the world’s first natural photodynamic solution, combining sunlight and botanicals to offer a natural option for maintaining cellular balance and supporting overall health. By integrating outdoor sunlight exposure and plant-based dietary elements, individuals can pursue a more natural, holistic path to wellness,” explained Dr. Daniel Chen.
With its eco-friendly foundation and innovative integration of natural elements, GPDT is poised to contribute to a new era of health management—where the synergy of sunlight and nature takes centre stage.
Oxperial BioHealth has announced plans to debut PropoLight, the world’s first GPDT (Green Products Photodynamic Therapy) product, in the first half of 2025. Marketed as a premium health supplement, PropoLight is designed to support overall wellness, particularly for individuals seeking additional measures to maintain cellular health.
According to Oxperial BioHealth’s research partner, Shin-Yi Huang, the next steps for PropoLight involve obtaining further certifications and undergoing rigorous trials in both the UK and US. These steps aim to establish the groundwork for introducing a pharmaceutical-grade version of the product to the global market.
The upcoming launch of PropoLight marks a significant milestone in blending natural health products with lifestyle-based wellness solutions. Looking to the future, Oxperial BioHealth plans to expand its product line to include advanced pharmaceutical-grade options, further advancing holistic health innovation and support worldwide.
ENDS
- Share This Article
Got News You'd Like To Share With The World? Our Press Release Distribution Starts At Just £95
